Reviewed clinical summary · Source-linked · Educational use only

Which Exercise Best Improves Liver Hormones in Obese Men?

Hormone Insight visual abstract summarising exercise training and hepatokines in obese men.

Clinical Bottom Line

A 12-week trial finds aerobic, Tabata, and HIIT all reduce body fat and circulating hepatokines in obese men, with higher-intensity protocols producing the greatest reductions. PICO summary and commentary.

Summary: In a 12-week trial in obese men, continuous aerobic, Tabata, and high-intensity interval training all reduced body fat and circulating liver-derived hepatokines, with the higher-intensity Tabata and HIIT protocols producing the greatest reductions.

PICO Summary

ElementDetail
Population44 obese men in four groups of 11; 12-week randomised trial, Iran.
InterventionEndurance (continuous aerobic) training, Tabata, or HIIT, three 60-minute sessions weekly.
ComparisonNon-exercising control group maintaining usual lifestyle.
OutcomeSignificant group-by-time effects were seen for fetuin-B, FGF-21, FGL-1, selenoprotein P, weight, BMI, and body-fat percentage. Reductions in fetuin-B were greater in HIIT and Tabata versus control, and reductions in FGF-21 and FGL-1 were greater in all three exercise groups versus control, with the largest effects in the higher-intensity Tabata and HIIT arms. No adverse effects reported.
RCT Front Endocrinol (Lausanne) · 2025

Exercise and liver hepatokines in obese men

RCT · obese men · 12 weeks

Trial design
44 obese men, four arms Enrolled & assessed RANDOMISED 1:1:1:1 HIIT High-intensity intervals n = 11 Control Usual lifestyle n = 11 Change in FGF-21 (pg/mL)
Change from baseline — both arms
FGF-21 (pg/mL) Baseline Week 12 -26.2 vs CT HIIT Control
FGF-21 (HIIT vs CT)
-26.2
mean diff
Fetuin-B
-0.13
HIIT vs CT
FGL-1
-8.1
HIIT vs CT
Group×time p
0.007
FGF-21
⬡ Bottom Line

All exercise modalities lowered liver-derived hepatokines alongside fat loss, with HIIT and Tabata producing the largest FGF-21, fetuin-B, and FGL-1 reductions versus a non-exercising control.

Expert Commentary

This is a mechanistically oriented trial exploring a fashionable and biologically plausible target, the hepatokines, liver-secreted proteins such as fetuin-B, FGF-21, and selenoprotein P that are elevated in obesity and fatty liver and linked to insulin resistance. The coherent finding is that exercise of any modality lowered these markers alongside fat loss, with the higher-intensity Tabata and HIIT protocols doing so most, which fits the broader pattern that intensity drives metabolic adaptation and offers time-efficient options for patients short on time. I would, however, keep the interpretation cautious and resist over-reading the biomarkers. This is a small study of 44 men over 12 weeks, hepatokine levels were not linked to actual liver fat or histology, diet was uncontrolled, and the reductions tracked body-composition change, so it is unclear how much reflects a specific hepatic adaptation versus simple fat loss. The FGF-21 result is also nuanced, since FGF-21 biology is complex and lower circulating levels are not straightforwardly good. Can I use this with my patients? As supportive reinforcement of exercise rather than a biomarker strategy. It backs recommending higher-intensity interval training, where tolerated and appropriately screened, as a time-efficient way to improve obesity-related metabolic signalling, while the best exercise remains the one a patient will sustain.

References

Ataeinosrat A, Abednatanzi H, Hajesfandiari S, et al. Hepatokines modulation in obesity: which exercise training model is better in men with obesity? Front Endocrinol (Lausanne). 2025;16:1560453. doi:10.3389/fendo.2025.1560453

Educational use: Hormone Insight is intended for healthcare professionals and learners. Interpret each summary alongside the primary source, local guidance, and patient-specific clinical judgement.

Subscribe now

Welcome to Hormone Insight. Our mission is to support clinical decision-making with accessible, evidence-based insights from recent studies and trials.

© 2024-2026 Hormone Insight. All rights reserved.